The FDA's review of the BLA for bimekizumab for the treatment of psoriasis is continuing. A decision on the approval application has been delayed until the third quarter of this year. DermTwitter
by the end of June. No reason for the delay was provided in the company's press release.
Bimekizumab is a monoclonal antibody that inhibits interleukin -17A and IL-17F, two drivers of inflammation. The manufacturer, UCB, is seeking approval in the United States for the treatment of adults with moderate to severeThe biologic has been approved for the treatment of moderate to severe psoriasis in the European Union as well as in Canada, Australia, Japan, and Saudi Arabia. It is marketed as Bimzelx.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Hydration nation: Clients clamor for IV therapy on demand even though it’s not FDA-approvedAre IV therapy 'bars' and stations worth all the hype? Fox News Digital spoke to multiple experts about the benefits and risks of these on-demand hydration facilities.
Weiterlesen »
Dublin family celebrates FDA approval of gene therapy for Duchenne developed in Central Oh'It is huge. It’s going to change the course of this disease,' said Dublin mom Amber Nisley. 'I mean, it truly is a game changer. This has never happened before
Weiterlesen »
AC Immune’s stock soars 13% after FDA grants fast-track designation to Alzheimer’s treatmentAC Immune SA’s stock soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track...
Weiterlesen »
Thousands of unauthorized vapes are pouring into the US despite the FDA crackdown on fruity flavorsThe trend underscores the FDA’s inability to control the tumultuous vaping market previously dominated by Juul and other reusable e-cigarettes.
Weiterlesen »
Thousands of unauthorized vapes are pouring into the US despite the FDA crackdown on fruity flavorsThe trend underscores the FDA’s inability to control the tumultuous vaping market previously dominated by Juul and other reusable e-cigarettes.
Weiterlesen »